Tuberculosis Therapeutics Market Growth, Size, Trends Analysis - By Disease Type, By Therapy, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Tuberculosis Therapeutics Market Introduction and Overview

According to SPER market research, 'Global Tuberculosis Therapeutics Market Size- By Disease Type, By Therapy, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Tuberculosis Therapeutics Market is predicted to reach 3.77 billion by 2034 with a CAGR of 5.38 %.

Drugs and treatment plans intended to prevent, manage, and cure tuberculosis (TB), a communicable bacterial infection brought on by Mycobacterium tuberculosis, are referred to as TB therapies. Antibiotics such isoniazid, rifampicin, ethambutol, and pyrazinamide are part of the standard treatment, which is usually given over a period of six months. Shorter treatment durations, better drug formulations.

Restraints: The growing incidence of extensively drug-resistant (XDR-TB) and multidrug-resistant (MDR-TB) market for TB treatments. Effective TB management is hampered by high drug costs, poor healthcare infrastructure, and restricted access to cutting-edge therapies in low-income nations. Inadequate research funding and drawn-out medication approval procedures impede the creation of innovative medicines.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Disease Type, By Therapy, By Route of Administration.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Cipla Limited, GlaxoSmithKline, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. and others.

Tuberculosis Therapeutics Market Segmentation:

By Disease Type: Based on the Disease Type, Global Tuberculosis Therapeutics Market is segmented as; Active TB, Latent TB.

By Therapy: Based on the Therapy, Global Tuberculosis Therapeutics Market is segmented as; First-Line Therapy, Second-Line Therapy.

By Route of Administration: Based on the Route of Administration, Global Tuberculosis Therapeutics Market is segmented as; Oral, Parenteral, Others.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Product Code: HLCA2542

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Tuberculosis Therapeutics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tuberculosis Therapeutics Market

7. Global Tuberculosis Therapeutics Market, By Disease Type (USD Million) 2021-2034

7.1. Active TB
7.2. Latent TB

8. Global Tuberculosis Therapeutics Market, By Therapy (USD Million) 2021-2034

8.1. First-Line Therapy
8.2. Second-Line Therapy

9. Global Tuberculosis Therapeutics Market, By Route of Administration (USD Million) 2021-2034

9.1. Oral
9.2. Parenteral
9.3. Others

10. Global Tuberculosis Therapeutics Market, (USD Million) 2021-2034

10.1. Global Tuberculosis Therapeutics Market Size and Market Share

11. Global Tuberculosis Therapeutics Market, By Region, (USD Million) 2021-2034

11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America

12. Company Profile

12.1. Cipla Limited
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
12.2. GlaxoSmithKline
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
12.3. Johnson & Johnson
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
12.4. Lupin Limited
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
12.5. Merck & Co., Inc.
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
12.6. Novartis AG
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
12.7. Pfizer Inc.
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
12.8. Sanofi
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
12.9. Sun Pharmaceutical Industries Ltd.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
12.10. Others